Fas-ligand and caspase-3 positivity in three cases of histiocytic sarcoma: a different etiopathogenic pathway? by Oliveira, Cristiano Claudino et al.
Autopsy and Case Reports. ISSN 2236-1960. Copyright © 2018. This is an Open Access article distributed 
under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted 
non-commercial use, distribution, and reproduction in any medium provided the article is properly cited.
a São Paulo State University (UNESP), Botucatu School of Medicine (FMB), Department of Pathology. Botucatu, SP, Brazil.
b PhD Pathology Laboratory. São Paulo, SP, Brazil.
Fas-ligand and caspase-3 positivity in three cases of histiocytic 
sarcoma: a different etiopathogenic pathway?
Cristiano Claudino Oliveiraa, Rafael Bispo Paschoalinib,  
Maria Aparecida Custódio Dominguesa
How to cite: Oliveira CC, Paschoalini RB, Domingues MAC. Fas-ligand and caspase-3 positivity in three cases of 
histiocytic sarcoma: a different etiopathogenic pathway? Autops Case Rep [Internet]. 2018;8(1):e2018001.  
http://dx.doi.org/10.4322/acr.2018.001
Letter to the Editor
ABSTRACT
Histiocytic sarcoma (HS) is a rare malignant neoplasia of hematopoietic origin and unknown etiology. We studied 
three patients with histiocytic sarcoma reviewing the morphological and immunohistochemical aspects. We evaluated 
in particular, if apoptosis may be unbalanced in this disease. All cases have morphological and immunohistochemical 
features consistent with the diagnosis of histiocytic sarcoma. The markers CD163, CD68, vimentin, lysozyme, and S-100 
were positive in all cases. Similarly, the three samples were positive for Fas-ligand and Caspase-3. It is well-known that 
neoplasms may induce increased levels of Fas-ligand with the blockade of the apoptosis process. In the context of HS, 
the increased Fas-ligand expression represents a new area for research. Indeed, it is linked to proinflammatory stimulus 
and, maybe with the association of an infection. 
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Dear editors,
Histiocytic sarcoma (HS) is a rare hematopoietic 
malignancy of unknown etiology.1,2 The diagnosis 
is made after ruling out other neoplasms such as 
melanoma, undifferentiated carcinomas, and anaplastic 
lymphomas.2,3 The use of immunohistochemical markers 
such as CD163, CD68, and lysozyme is mandatory for 
a definitive diagnosis.2 The histiocytic marker CD163 
has been proposed as the most specific.2,3
We present the immunohistochemical behavior of 
apoptotic marker pathways in three cases of HS under 
our service. We believe that the apoptosis’ mechanisms 
might contribute to understanding the etiology of this 
disease.
The first case is a 30-year-old man with painful 
cutaneous lesions on the left thorax, intermittent fever, 
unmeasured weight loss and bilateral cervical/axillary 
adenomegaly. The second case is a 66-year-old 
woman with four months of non-painful left cervical 
adenomegaly, without B-symptoms. She had a 
melanoma 23 years ago. And, the third patient is 
a 42-year-old woman with abdominal pain and a 
palpable mass in the small intestine.
We reviewed the morphological aspects, using 
the criteria supported by Hornick et al.4 These 
histopathological aspects were (i) cell size; (ii) chromatin 
pattern; (iii) evident nucleolus; (iv) nuclear inclusion; 
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(v) cytoplasm aspect; (vi) presence of bizarre types 
of cell; (vii) the presence of giant cells; and (viii) the 
presence of Reed-Sternberg-like cells or rhabdoid cells 
or xanthomized cells. Other relevant morphological 
aspects, also cited by literature, are cohesivity, 
epithelioid features, fusiform features, inflammatory 
infiltrate, phagocytosis, apoptosis, mitosis, necrosis, 
and hemosiderin.2,4
We also performed the immunohistochemistry 
study with cytokeratin (AE1/AE3), EMA, Vimentin, 
S100 protein, HMB-45, Melan-A, Myeloperoxidase 
(MPO), CD21, CD1a, CD35, CD45, CD15, CD30, CD20, 
CD3, CD68, Lysozyme, and CD163. Additionally, we 
used Fas Ligand, Bax and Caspase-3 to study apoptosis. 
For immunohistochemical characterization, the 
antibody-staining pattern was considered and classified 
as either diffuse or focal.
We confirmed the diagnosis of HS in all three 
cases. Twelve relevant morphological criteria were 
simultaneously present in all the HS cases2-4 with 
minimal variability. There were: medium to large cell 
size, vacuolated chromatin, irregular cell membrane, 
intranuclear inclusion, vacuolar eosinophilic cytoplasm, 
the presence of bizarre cells, cohesivity, epithelioid 
features, phagocytosis, inflammatory background, 
apoptosis and hemosiderin (Table 1).
The final immunohistochemical characterization of 
all the HS cases is summarized in Table 2. CD163, CD68, 
vimentin, and lysozyme were positive in all patients. 
Only S-100 protein was not uniform, and its positivity 
was focal or irregular. Concerning apoptosis, two 
markers showed positive results in all three cases: 
Fas-ligand and caspase-3. The Bax marker was negative 
in all of the cases. Figure 1 and 2 show some images 
of the results.
Fas  and  Fas - l igand  a re  t ransmembrane 
glycoproteins, whose connections can start apoptosis.5,6 
Fas and Fas-ligand are also named CD95 and CD95L 
and are part of the tumor necrosis factor receptor 
family. Natural ligand (CD95L or Fas-ligand) or agonistic 
antibodies may stimulate the receptor.7 Fibroblasts, 
epithelial cells, tumor cells and hematopoietic cells have 
Table 1. Morphological comparison of the three cases
Morphology Case #1 Case #2 Case #3
cell size Cells proportional to 4 lymphocytes
Cells proportional to 6 
lymphocytes
Cells proportional to 4 
lymphocytes
vacuolated chromatin Present Present Present
irregular nuclear membrane Present Present Present
inclusion Present Present Present
vacuolated eosinophilic 
cytoplasm Present Present Present
bizarre cells Present (few) Present Present
cohesivity Present Present Present
epithelioid features Present Present Present
inflammatory infiltration Present (polymorphonuclear) Present (lymphocytic) Present (lymphocytic and eosinophilic)
phagocytosis Present Present Present
apoptosis Present Present Present
hemosiderin Present Present Present
nucleolus Present (Variable) Present Present (Variable)
“Reed-Sternberg-like” cells Present (low number) Present Present
rhabdoid cells Present Absent Present
giant cells Absent Present Present
xanthomatous cells Absent Absent Present
fusiform appearance Absent Present Present
mitotic figures Present (low number) Present Present
necrosis Present Absent Present (minimal)
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Fas receptors. Inflammatory, necrosis and bacterial 
infections may activate the Fas-ligand. In microbial 
infections, there is a marked proinflammatory scenario 
with activation of Fas-ligand and therefore Fas-ligand 
induced apoptosis.5
Fas/FasL has an important function in killing 
cancer cells. Cytotoxic lymphocytes recognize the 
tumor cells in an antigen-specific mechanism and these 
cells are attacked by direct systems: perforin/granzyme 
or the CD95/CD95L engagement. Other pathways 
activated an upregulation of TNFα and INFγ, which 
cause more expression of Fas receptors, inducting cell 
death. However, the Fas/Fas ligand system plays many 
roles in cancer. Indirect roles are the suppression of the 
immune response in the cancer micro-environment by 
either tumor-generated CD95L or by CD95L expressed 
by endothelial cells. The main direct effect is the 
promotion of tumor growth and invasiveness. Another 
Table 2. Comparative immunohistochemical study of 
the three cases
Positive (all) Negative (all) Variable
CD163 (diffuse) AE1/AE3 CD45*
CD68 (diffuse) EMA CD30*
Vimentin (diffuse) MELAN-A
Lysozyme (diffuse) CD20
S-100 (focal) CD3
Caspase (focal) CD15
Fas-ligand (diffuse) MPO
CD21
CD35
CD1a
HMB45
Bax
*A cutaneous lesion was present only in case 01.
Figure 1. Immunohistochemical markers. A – Caspase 3, focal, 200x; B – CD45, in histological section of skin, 200x; 
C – CD68, diffuse, 400x; D – CD163, diffuse, 400x.
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point is the low baseline level of CD95/CD95L signaling 
in cancer cells which is important for their survival.7
Cancers such as hepatocellular and esophageal 
carcinoma, lymphoma, melanoma and gastric 
adenocarcinoma express Fas-ligand, inducing apoptosis 
by the T-cell, which presents the Fas receptor. 
Fas-ligand was primarily recognized as associated 
with the remodeling tissue and deletion of potentially 
autoreactive cell in thymus, maintaining immune 
tolerance. Thus, the apoptosis process occurs, again, 
in a context of inflammation, in this case, due to a 
neoplasm.5,6
The relationship of apoptosis reduction and 
lymphoma was first described in the foll icular 
lymphoma due to positive Bcl-2, an anti-apoptotic 
protein, followed by other neoplasms with imbalances 
of pro-apoptotic and anti-apoptotic factors.6 In some 
Figure 2. Immunohistochemical markers. A – Fas-ligand, diffuse, 1000x; B – Lysozym, diffuse, 200x; C – S-100, 
focal, 200x; and D – Vimentin, diffuse, 400x.
types of leukemia the Fas-ligand is expressed on the 
plasmatic membrane of the neoplastic cells, which 
bind to T-cell with Fas expression. Due to this coupling, 
apoptosis ensues, and the immune action against the 
tumor is blocked.5,6
Here, we present an unusual finding of HS. 
Apoptosis and neoplasms have been studied for 
many years, but, in the context of HS, we could 
not find any report on this observation in humans. 
HS is an aggressive and a controversial disease in the 
literature. Therefore, supplementary knowledge about 
its etiology is needed.
These three cases are not conclusive due to the 
small series’ size. However, they represent another 
possibility in understanding HS. In addition to the 
potential site for future therapies, the inquiry remains 
on finding out what factors may stimulate Fas-ligand. 
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Infection and the inflammatory response as well as the 
microenvironment alterations are possibilities that may 
contribute to neoplasm growth.
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